TNXP Tonix Pharmaceuticals | $0.20 +11.3% | 2/28/2024 | Initiated by | Dawson James | - | Buy | $3.00 | Low | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 2/28/2024 |
DARE Daré Bioscience | $0.49 +11.5% | 1/30/2024 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 1/30/2024 |
BYRN Byrna Technologies | $11.71 -2.3% | 9/27/2023 | Downgraded by | Dawson James | - | Buy -> Neutral | | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/27/2023 |
XXII 22nd Century Group | $1.39 -8.6% | 8/15/2023 | Target Lowered by | Dawson James | - | Buy -> Buy | $160.00 -> $120.00 | Low | View details for Dawson James rating of 22nd Century Group (NASDAQ:XXII) on 8/15/2023 |
XXII 22nd Century Group | $1.39 -8.6% | 7/25/2023 | Target Lowered by | Dawson James | - | | $240.00 -> $160.00 | Low | View details for Dawson James rating of 22nd Century Group (NASDAQ:XXII) on 7/25/2023 |
BYRN Byrna Technologies | $11.71 -2.3% | 7/12/2023 | Target Lowered by | Dawson James | - | | $9.50 -> $7.25 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 7/12/2023 |
|
TOON Kartoon Studios | $1.06 -0.9% | 7/11/2023 | Target Lowered by | Dawson James | - | | $12.50 -> $10.00 | Low | View details for Dawson James rating of Kartoon Studios (NASDAQ:TOON) on 7/11/2023 |
XXII 22nd Century Group | $1.39 -8.6% | 7/3/2023 | Target Lowered by | Dawson James | - | | $1,080.00 -> $240.00 | Low | View details for Dawson James rating of 22nd Century Group (NASDAQ:XXII) on 7/3/2023 |
NRXP NRx Pharmaceuticals | $3.54 +0.6% | 3/17/2023 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/17/2023 |
SMSI Smith Micro Software | $2.72 +1.5% | 2/28/2023 | Target Lowered by | Dawson James | - | | $66.40 -> $28.00 | Low | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 2/28/2023 |
ZOM Zomedica | $0.17 -5.4% | 1/6/2023 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Zomedica (NYSEAMERICAN:ZOM) on 1/6/2023 |
ZOM Zomedica | $0.17 -5.4% | 1/6/2023 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Zomedica (NYSEAMERICAN:ZOM) on 1/6/2023 |
BCDA BioCardia | $0.39
| 11/11/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 11/11/2022 |
CHEK Check-Cap | $2.19 -2.2% | 9/15/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 9/15/2022 |
BYRN Byrna Technologies | $11.71 -2.3% | 9/8/2022 | Target Lowered by | Dawson James | - | | $12.00 -> $9.50 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/8/2022 |
PRPH ProPhase Labs | $5.03 -1.6% | 7/21/2022 | Downgraded by | Dawson James | - | Neutral -> Sell | | Low | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 7/21/2022 |
DYAI Dyadic International | $1.65 -0.6% | 7/18/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 7/18/2022 |
BYRN Byrna Technologies | $11.71 -2.3% | 4/26/2022 | Initiated by | Dawson James | - | Buy | $12.00 | High | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 4/26/2022 |
LCTX Lineage Cell Therapeutics | $1.08 +1.9% | 3/11/2022 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 3/11/2022 |
SMSI Smith Micro Software | $2.72 +1.5% | 3/11/2022 | Target Lowered by | Dawson James | - | Buy | $91.20 -> $66.40 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 3/11/2022 |
PFIE Profire Energy | $1.38 -2.8% | 3/9/2022 | Target Raised by | Dawson James | - | | $1.65 -> $2.00 | Low | View details for Dawson James rating of Profire Energy (NASDAQ:PFIE) on 3/9/2022 |
KNWN Know Labs | $0.65 -7.1% | 2/8/2022 | Initiated by | Dawson James | - | Buy | $7.00 | High | View details for Dawson James rating of Know Labs (OTCMKTS:KNWN) on 2/8/2022 |
CHEK Check-Cap | $2.19 -2.2% | 2/7/2022 | Upgraded by | Dawson James | - | Neutral -> Buy | | High | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 2/7/2022 |
XXII 22nd Century Group | $1.39 -8.6% | 1/6/2022 | Target Raised by | Dawson James | Analyst James McIlree | Buy -> Buy | $1,680.00 -> $2,040.00 | N/A | View details for Dawson James rating of 22nd Century Group (NASDAQ:XXII) on 1/6/2022 |
BCLI Brainstorm Cell Therapeutics | $0.52
| 12/22/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Neutral | | Medium | View details for Dawson James rating of Brainstorm Cell Therapeutics (NASDAQ:BCLI) on 12/22/2021 |
VUZI Vuzix | $1.42 -5.3% | 12/21/2021 | Initiated by | Dawson James | - | Buy | $15.00 | Medium | View details for Dawson James rating of Vuzix (NASDAQ:VUZI) on 12/21/2021 |
PRPH ProPhase Labs | $5.03 -1.6% | 10/13/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 10/13/2021 |
PFIE Profire Energy | $1.38 -2.8% | 8/5/2021 | Initiated by | Dawson James | Analyst James McIlree | Buy | $1.65 | High | View details for Dawson James rating of Profire Energy (NASDAQ:PFIE) on 8/5/2021 |
SMSI Smith Micro Software | $2.72 +1.5% | 8/5/2021 | Initiated by | Dawson James | - | Buy | $88.80 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 8/5/2021 |
AVXL Anavex Life Sciences | $4.55 +1.1% | 6/21/2021 | Target Raised by | Dawson James | - | Buy | $19.00 -> $35.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/21/2021 |
BCDA BioCardia | $0.39
| 4/22/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/22/2021 |
BCDA BioCardia | $0.39
| 4/16/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | High | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/16/2021 |
CHEK Check-Cap | $2.19 -2.2% | 3/17/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | $40.00 | Low | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 3/17/2021 |
CTXR Citius Pharmaceuticals | $0.65 -3.0% | 2/25/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | Low | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 2/25/2021 |
FBIO Fortress Biotech | $1.93 +9.7% | 2/17/2021 | Target Raised by | Dawson James | - | Buy | $240.00 -> $315.00 | Low | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 2/17/2021 |
PRPH ProPhase Labs | $5.03 -1.6% | 1/20/2021 | Initiated by | Dawson James | - | Buy | $25.00 | High | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 1/20/2021 |
LCTX Lineage Cell Therapeutics | $1.08 +1.9% | 10/12/2020 | Reiterated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 10/12/2020 |
CTXR Citius Pharmaceuticals | $0.65 -3.0% | 9/17/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/17/2020 |
DARE Daré Bioscience | $0.49 +11.5% | 7/12/2020 | Reiterated by | Dawson James | - | Buy | $3.00 | High | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 7/12/2020 |
AVXL Anavex Life Sciences | $4.55 +1.1% | 6/8/2020 | Reiterated by | Dawson James | - | Buy | $16.00 | Medium | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/8/2020 |
Shocking $16T Elon Musk Crypto Leak (Ad) Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. |
CTSO Cytosorbents | $0.97 +11.5% | 3/9/2020 | Reiterated by | Dawson James | - | Buy | $15.00 -> $17.00 | High | View details for Dawson James rating of Cytosorbents (NASDAQ:CTSO) on 3/9/2020 |
DYAI Dyadic International | $1.65 -0.6% | 2/26/2020 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | | High | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 2/26/2020 |
IMAC IMAC | $3.38 +7.6% | 1/14/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of IMAC (NASDAQ:IMAC) on 1/14/2020 |
MESO Mesoblast | $7.35 +4.7% | 12/19/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $28.00 | Low | View details for Dawson James rating of Mesoblast (NASDAQ:MESO) on 12/19/2019 |
CHEK Check-Cap | $2.19 -2.2% | 12/5/2019 | Initiated by | Dawson James | - | Buy | $80.00 | Low | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 12/5/2019 |
DYAI Dyadic International | $1.65 -0.6% | 10/16/2019 | Initiated by | Dawson James | - | Buy | $14.00 | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 10/16/2019 |
BCDA BioCardia | $0.39
| 9/17/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $24.00 | Low | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
BCDA BioCardia | $0.39
| 9/17/2019 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Medium | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
CTXR Citius Pharmaceuticals | $0.65 -3.0% | 9/6/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $7.00 | N/A | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/6/2019 |
FBIO Fortress Biotech | $1.93 +9.7% | 8/26/2019 | Initiated by | Dawson James | - | Buy | $285.00 | High | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 8/26/2019 |
ADMA ADMA Biologics | $9.21 +1.7% | 8/12/2019 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | $4.00 | High | View details for Dawson James rating of ADMA Biologics (NASDAQ:ADMA) on 8/12/2019 |
AVXL Anavex Life Sciences | $4.55 +1.1% | 7/24/2019 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $16.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 7/24/2019 |
INTT inTEST | $9.88 -2.9% | 12/28/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of inTEST (NYSE:INTT) on 12/28/2018 |
ORGS Orgenesis | $0.55 +3.8% | 12/20/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Orgenesis (NASDAQ:ORGS) on 12/20/2018 |
SSNT SilverSun Technologies | $15.40 -5.3% | 12/19/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of SilverSun Technologies (NASDAQ:SSNT) on 12/19/2018 |
BCLI Brainstorm Cell Therapeutics | $0.52
| 12/18/2018 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | High | View details for Dawson James rating of Brainstorm Cell Therapeutics (NASDAQ:BCLI) on 12/18/2018 |
ORGS Orgenesis | $0.55 +3.8% | 12/20/2018 | Initiated by | Dawson James | - | Buy -> Buy | | Medium | View details for Dawson James rating of Orgenesis (NASDAQ:ORGS) on 12/20/2018 |
WYY WidePoint | $2.69 +1.9% | 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of WidePoint (NYSEAMERICAN:WYY) on 12/3/2018 |
WTT Wireless Telecom Group | $2.13
| 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Wireless Telecom Group (NYSEAMERICAN:WTT) on 12/3/2018 |
CNVS Cineverse | $1.02 -3.8% | 10/22/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Cineverse (NASDAQ:CNVS) on 10/22/2018 |
FRX Fennec Pharmaceuticals | C$9.51 +1.9% | 10/10/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | N/A | View details for Dawson James rating of Fennec Pharmaceuticals (TSE:FRX) on 10/10/2018 |
FENC Fennec Pharmaceuticals | $7.04 -1.1% | 10/11/2018 | Initiated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Fennec Pharmaceuticals (NASDAQ:FENC) on 10/11/2018 |
LUNA Luna Innovations | $3.01 +2.0% | 10/2/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Luna Innovations (NASDAQ:LUNA) on 10/2/2018 |
SSKN STRATA Skin Sciences | $0.39 +2.6% | 9/4/2018 | Initiated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of STRATA Skin Sciences (NASDAQ:SSKN) on 9/4/2018 |
VERU Veru | $1.32 -3.6% | 6/25/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Medium | View details for Dawson James rating of Veru (NASDAQ:VERU) on 6/25/2018 |
LVO LiveOne | $1.83 +1.1% | 6/4/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Medium | View details for Dawson James rating of LiveOne (NASDAQ:LVO) on 6/4/2018 |
ALT Altimmune | $8.01 -10.0% | 5/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Altimmune (NASDAQ:ALT) on 5/29/2018 |
ACST Acasti Pharma | $2.69 -2.5% | 1/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Low | View details for Dawson James rating of Acasti Pharma (NASDAQ:ACST) on 1/29/2018 |
CVM CEL-SCI | $1.27 -9.3% | 10/16/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Neutral | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 10/16/2017 |
PAVM PAVmed | $1.79 -4.8% | 9/5/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $151.50 | High | View details for Dawson James rating of PAVmed (NASDAQ:PAVM) on 9/5/2017 |
TNXP Tonix Pharmaceuticals | $0.20 +11.3% | 8/23/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $18,000.00 | Medium | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 8/23/2017 |
EPIX ESSA Pharma | $5.70 -8.8% | 8/3/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of ESSA Pharma (NASDAQ:EPIX) on 8/3/2017 |
CVM CEL-SCI | $1.27 -9.3% | 3/11/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/11/2016 |
ENZ Enzo Biochem | $1.09 -1.8% | 2/9/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of Enzo Biochem (NYSE:ENZ) on 2/9/2016 |
SLNO Soleno Therapeutics | $46.16 +1.1% | 5/6/2015 | Initiated by | Dawson James | - | Buy | $952.50 | N/A | View details for Dawson James rating of Soleno Therapeutics (NASDAQ:SLNO) on 5/6/2015 |
CVM CEL-SCI | $1.27 -9.3% | 3/2/2015 | Initiated by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/2/2015 |
AXGN AxoGen | $6.04 +1.2% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $5.00 | N/A | View details for Dawson James rating of AxoGen (NASDAQ:AXGN) on 5/14/2014 |
NEO NeoGenomics | $14.80 -1.3% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of NeoGenomics (NASDAQ:NEO) on 5/14/2014 |
ABIO ARCA biopharma | $3.33 -16.8% | 10/9/2013 | Initiated by | Dawson James | - | Buy | $3.75 | N/A | View details for Dawson James rating of ARCA biopharma (NASDAQ:ABIO) on 10/9/2013 |
AGEN Agenus | $10.86 +3.4% | 3/12/2013 | Reiterated by | Dawson James | - | Buy | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 3/12/2013 |
MD Pediatrix Medical Group | $7.74 -0.6% | 3/12/2013 | Downgraded by | Dawson James | - | Buy -> Neutral | $80.00 | N/A | View details for Dawson James rating of Pediatrix Medical Group (NYSE:MD) on 3/12/2013 |
ARWR Arrowhead Pharmaceuticals | $24.77 -0.9% | 2/26/2013 | Initiated by | Dawson James | - | Buy | $4.00 | N/A | View details for Dawson James rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/26/2013 |
ATOS Atossa Therapeutics | $1.57 -2.5% | 12/20/2012 | Initiated by | Dawson James | - | Outperform | $120.00 | N/A | View details for Dawson James rating of Atossa Therapeutics (NASDAQ:ATOS) on 12/20/2012 |
BMY Bristol-Myers Squibb | $44.03 -0.2% | 12/12/2012 | Reiterated by | Dawson James | - | Market Outperform | $51.00 | N/A | View details for Dawson James rating of Bristol-Myers Squibb (NYSE:BMY) on 12/12/2012 |
AMGN Amgen | $312.47 -0.7% | 12/7/2012 | Initiated by | Dawson James | - | Outperform | $91.00 | N/A | View details for Dawson James rating of Amgen (NASDAQ:AMGN) on 12/7/2012 |
GEO The GEO Group | $13.42 +1.4% | 12/4/2012 | Downgraded by | Dawson James | - | Market Perform | | N/A | View details for Dawson James rating of The GEO Group (NYSE:GEO) on 12/4/2012 |
SRPT Sarepta Therapeutics | $131.38 -1.0% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/27/2012 |
RMTI Rockwell Medical | $1.77 +1.1% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $132.00 | N/A | View details for Dawson James rating of Rockwell Medical (NASDAQ:RMTI) on 11/27/2012 |
AGEN Agenus | $10.86 +3.4% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 11/27/2012 |
SLS SELLAS Life Sciences Group | $1.46 -0.7% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $150.00 | N/A | View details for Dawson James rating of SELLAS Life Sciences Group (NASDAQ:SLS) on 11/27/2012 |
Shocking $16T Elon Musk Crypto Leak (Ad) Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. |
CYTK Cytokinetics | $59.53 -0.7% | 11/27/2012 | Downgraded by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Cytokinetics (NASDAQ:CYTK) on 11/27/2012 |
GALT Galectin Therapeutics | $3.23 +2.9% | 7/6/2012 | Target Lowered by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of Galectin Therapeutics (NASDAQ:GALT) on 7/6/2012 |
TNXP Tonix Pharmaceuticals | $0.20 +11.3% | 4/26/2012 | Initiated by | Dawson James | - | Buy | $8,000.00 | N/A | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 4/26/2012 |
NFLX Netflix | $621.10 +1.7% | 10/28/2011 | Target Lowered by | Dawson James | - | Sell | $16.50 -> $7.14 | N/A | View details for Dawson James rating of Netflix (NASDAQ:NFLX) on 10/28/2011 |